A London-based financial analyst has raised the price target for Sandoz to a record high, reinforcing confidence in the pharmaceutical spin-off following its entry into the Swiss Market Index (SMI).
Meanwhile, market sentiment surrounding broader Swiss equities shows signs of division. A Basel-based private bank has expressed a more cautious outlook, suggesting that Swiss stocks may no longer hold their previous favored status among investors.
In a related development, UBS has highlighted Swiss equities prominently on its list of least attractive stock markets, underscoring diverging analyst perspectives on valuations and sector performance within the region.
